BRAF and non-small cell lung carcinoma: A recent study indicated that BRAF-mutant tumors exhibited similar CD8+ T cells to regulatory T-cell ratios, cytotoxic gene expression signatures, immune suppressive features, and biomarkers associated with immune checkpoint inhibitor response as wild-type NSCLC [59], whereas others report limited efficacy of checkpoint inhibitors in this population [60].